In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Compass Therapeutics, with a price target of $24.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Compass Therapeutics’ promising pipeline and financial outlook. The company has recently announced positive pivotal topline results from its COMPANION-002 study, which exceeded benchmark expectations. This study involves tovecimig, a bispecific DLL4/VEGF-A antibody, in combination with paclitaxel for patients with advanced BTC. The results suggest a positive impact on overall survival, with fewer deaths observed than initially projected, indicating the potential effectiveness of tovecimig.
Additionally, Compass Therapeutics is making strides with its other assets. The CTX-8371, a PD-1 x PD-L1 bispecific, has shown promising efficacy signals in its Phase 1 study, with significant reductions in tumor burden in patients with NSCLC and TNBC. The company plans to expand this study and present detailed findings soon. Furthermore, the advancement of CTX-10726, a novel PD-1 x VEG-F bispecific, with an expected IND in 4Q25 and promising preclinical data, adds to the positive outlook. Financially, the company remains strong, with a cash runway expected to last into 2027, supporting its ongoing and future developments.
According to TipRanks, Pantginis is an analyst with an average return of -14.7% and a 32.67% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Cytokinetics, and Capricor Therapeutics.